

## CONTENTS

NOTE TO THE READER .....	9
LIST OF PARTICIPANTS .....	11
PREAMBLE .....	17
Background .....	17
Objective and Scope .....	17
Selection of Topics for Monographs .....	18
Data for Monographs .....	19
The Working Group .....	19
Working Procedures .....	19
Exposure Data .....	20
Studies of Cancer in Humans .....	21
Studies of Cancer in Experimental Animals .....	25
Other Data Relevant to an Evaluation of Carcinogenicity and Its Mechanisms ..	27
Summary of Data Reported .....	29
Evaluation .....	30
References .....	34
GENERAL REMARKS .....	39
THE MONOGRAPHS	
<b>Infection with schistosomes (<i>Schistosoma haematobium</i>, <i>S. mansoni</i> and <i>S. japonicum</i>) .</b>	<b>45</b>
1. Exposure data .....	45
1.1 Structure and biology of schistosomes .....	45
1.1.1 Taxonomy .....	45
1.1.2 Structure .....	45
1.1.3 Life cycle and biology of the adult worm .....	46
1.2 Methods for detection of infection .....	48
1.2.1 History taking .....	48
1.2.2 Clinical diagnosis .....	48
1.2.3 Parasitological tests .....	49
1.2.4 Immunological tests .....	49
1.2.5 Establishment of absence of infection .....	50

## CONTENTS

1.3	Epidemiology of infection	50
1.3.1	Geographical distribution	50
1.3.2	Risk factors for infection	55
1.3.3	Aggregation of infection	55
1.3.4	Prevalence and intensity of infection	55
1.3.5	Sex-related patterns of infection	58
1.3.6	Relationship of morbidity to intensity of infection	58
1.3.7	Relationship of morbidity to mortality from infection	58
1.4	Clinical disease in humans (other than cancer)	59
1.5	Treatment and control	61
1.5.1	Treatment	61
1.5.2	Control	62
2.	Studies of cancer in humans	63
2.1	Descriptive studies	63
2.1.1	<i>Schistosoma haematobium</i>	63
2.1.2	<i>Schistosoma mansoni</i>	66
2.1.3	<i>Schistosoma japonicum</i>	67
2.2	Case reports and case series	70
2.2.1	<i>Schistosoma haematobium</i>	71
2.2.2	<i>Schistosoma mansoni</i>	72
2.2.3	<i>Schistosoma japonicum</i>	73
2.3	Cohort study	73
2.4	Case-control studies (with retrospective exposure assessment)	74
2.4.1	<i>Schistosoma haematobium</i>	74
2.4.2	<i>Schistosoma japonicum</i>	77
3.	Studies of cancer in animals	81
3.1	Infection with <i>Schistosoma haematobium</i> alone	81
3.1.1	Mouse	81
3.1.2	Rat	81
3.1.3	Hamster	82
3.1.4	Opossum	82
3.1.5	Nonhuman primate	82
3.2	Infection with <i>Schistosoma haematobium</i> in combination with administration of known carcinogens	83
3.2.1	2-Acetylaminofluorene	83
3.2.2	<i>ortho</i> -Aminoazotoluene	84
3.2.3	<i>N</i> -Nitrosamines	84
3.3	Infection with <i>Schistosoma mansoni</i> alone	84
3.3.1	Mouse	84
3.3.2	<i>Mastomys natalensis</i>	85
3.3.3	Hamster	85
3.3.4	Nonhuman primate	85

## CONTENTS

3.4	Infection with <i>Schistosoma mansoni</i> in combination with administration of known carcinogens	86
3.4.1	2-Amino-5-azotoluene	86
3.4.2	2-Naphthylamine and 2-acetylaminofluorene	86
3.5	Infection with <i>Schistosoma mansoni</i> in combination with administration of compounds used or evaluated in the past as antischistosomal agents	87
3.6	Infection with <i>Schistosoma japonicum</i> alone	87
3.7	Infection with <i>Schistosoma japonicum</i> in combination with administration of known carcinogens	87
3.7.1	Dimethylaminobenzene	87
3.7.2	2-Acetylaminofluorene	88
4.	Other data relevant for evaluation of carcinogenicity and its mechanisms	88
4.1	Pathology of infection	88
4.1.1	Humans	88
4.1.2	Experimental systems	92
4.2	Other observations relevant to the interpretation of carcinogenicity and mechanisms of carcinogenesis	93
4.2.1	Humans	93
4.2.2	Experimental systems	95
5.	Summary of data reported and evaluation	96
5.1	Exposure data	96
5.2	Human carcinogenicity data	97
5.3	Animal carcinogenicity data	99
5.4	Other relevant data	99
5.5	Evaluation	99
6.	References	100
<b>Infection with liver flukes (<i>Opisthorchis viverrini</i>, <i>O. felineus</i> and <i>Clonorchis sinensis</i>)</b>		<b>121</b>
1.	Exposure data	121
1.1	Structure and biology of liver flukes	121
1.1.1	Taxonomy	121
1.1.2	Structure	121
1.1.3	Life cycle and biology of the adult worm	122
1.1.4	Immune response to infection	124
1.2	Methods for detection of infection	124
1.2.1	Qualitative faecal examination for eggs	124
1.2.2	Quantitative faecal assessment of intensity of infection	125
1.2.3	Serological tests for helminth-specific antibody and antigen	125
1.2.4	Intradermal tests	126
1.3	Epidemiology of infection	126
1.3.1	Geographical distribution	126
1.3.2	Risk factors for infection	130

## CONTENTS

1.3.3	Age- and sex-related patterns of infection .....	132
1.3.4	Aggregation of infection .....	132
1.4	Clinical disease in humans (other than cancer) .....	134
1.5	Treatment and control .....	135
2.	Studies of cancer in humans .....	136
2.1	Descriptive studies .....	136
2.1.1	<i>Opisthorchis viverrini</i> .....	136
2.1.2	<i>Opisthorchis felineus</i> .....	137
2.2	Case reports and case series .....	137
2.2.1	<i>Opisthorchis viverrini</i> .....	137
2.2.2	<i>Opisthorchis felineus</i> .....	137
2.2.3	<i>Clonorchis sinensis</i> .....	141
2.3	Case-control studies .....	141
2.3.1	<i>Opisthorchis viverrini</i> .....	141
2.3.2	<i>Clonorchis sinensis</i> .....	143
3.	Studies of cancer in animals .....	144
3.1	Infection with <i>Opisthorchis viverrini</i> alone .....	144
3.2	Infection with <i>Opisthorchis viverrini</i> in combination with administration of known carcinogens .....	146
3.2.1	<i>N</i> -Nitrosodimethylamine .....	146
3.2.2	<i>N</i> -Nitrosodiethylamine .....	148
3.2.3	<i>N</i> -Nitrosodihydroxydi- <i>n</i> -propylamine .....	148
3.3	Infection with <i>Opisthorchis viverrini</i> in combination with administration of other modifying factors .....	149
3.4	Infection with <i>Opisthorchis felineus</i> .....	150
3.5	Infection with <i>Clonorchis sinensis</i> alone .....	150
3.5.1	Rat .....	150
3.5.2	Cat .....	150
3.5.3	Dog .....	150
3.6	Infection with <i>Clonorchis sinensis</i> in combination with administration of known carcinogens .....	150
3.6.1	Aflatoxin B <sub>1</sub> .....	150
3.6.2	<i>N</i> -Nitrosodimethylamine .....	151
3.6.3	2-Acetylaminofluorene .....	152
4.	Other data relevant for evaluation of carcinogenicity and its mechanisms ...	152
4.1	Pathology of infection .....	152
4.1.1	Humans .....	152
4.1.2	Experimental systems .....	155
4.1.3	Comparison of humans and experimental animals .....	157
4.2	Other observations relevant to the interpretation of carcinogenicity and mechanisms of carcinogenesis .....	157
4.2.1	Humans .....	157

## CONTENTS

4.2.2	Experimental systems .....	158
5.	Summary of data reported and evaluation .....	159
5.1	Exposure data .....	159
5.2	Human carcinogenicity data .....	160
5.3	Animal carcinogenicity data .....	161
5.4	Other relevant data .....	161
5.5	Evaluation .....	161
6.	References .....	162
<b>Infection with <i>Helicobacter pylori</i></b>	.....	<b>177</b>
1.	Exposure data .....	177
1.1	Structure and biology of <i>Helicobacter pylori</i> .....	177
1.1.1	Taxonomy .....	177
1.1.2	Biology .....	177
1.1.3	Agent–host relationship .....	179
1.2	Methods for detection of infection .....	181
1.2.1	Methods based on gastric biopsy specimens .....	181
1.2.2	Methods based on gastric juice samples .....	182
1.2.3	Methods based on faecal specimens .....	182
1.2.4	Methods based on dental plaque and saliva samples .....	182
1.2.5	Methods based on blood samples .....	183
1.2.6	Urea breath test .....	183
1.3	Epidemiology of infection .....	183
1.3.1	Prevalence .....	183
1.3.2	Risk factors for infection .....	184
1.3.3	Routes of transmission .....	186
1.4	Clinical disease in humans (other than cancer) .....	187
1.4.1	Gastritis .....	187
1.4.2	Duodenal ulcer disease .....	187
1.4.3	Gastric ulcer disease .....	187
1.4.4	Hypertrophic protein-losing gastritis .....	188
1.4.5	Childhood diseases .....	188
1.5	Treatment and control .....	188
1.5.1	Antibiotics and acid suppressive therapy .....	188
1.5.2	Vaccination .....	188
2.	Studies of cancer in humans .....	188
2.1	Descriptive studies .....	188
2.1.1	Geographical correlations .....	188
2.1.2	Time trends .....	191
2.1.3	Socioeconomic trends .....	191
2.2	Case series .....	191
2.2.1	Gastric carcinoma .....	191

## CONTENTS

2.2.2	Gastric lymphoma .....	192
2.3	Cohort studies .....	192
2.3.1	Gastric carcinoma .....	192
2.3.2	Gastric lymphoma .....	197
2.4	Case-control studies .....	197
2.4.1	Gastric carcinoma .....	197
2.4.2	Other cancers .....	203
2.5	Intervention studies .....	203
3.	Studies of cancer in experimental animals .....	203
3.1	Infection with <i>Helicobacter pylori</i> alone .....	203
3.2	Infection with <i>Helicobacter pylori</i> in combination with administration of known carcinogens .....	203
3.3	Infection with other <i>Helicobacter</i> species .....	205
3.4	Infection with other <i>Helicobacter</i> species in combination with administration of known carcinogens .....	205
4.	Other data relevant for evaluation of carcinogenicity and its mechanisms ...	206
4.1	Pathology of infection .....	206
4.1.1	Humans .....	206
4.1.2	Experimental systems .....	211
4.2	Other observations relevant to the interpretation of carcinogenicity and mechanisms of carcinogenesis .....	213
4.2.1	Humans .....	213
4.2.2	Experimental systems .....	217
5.	Summary of data reported and evaluation .....	218
5.1	Exposure data .....	218
5.2	Human carcinogenicity data .....	218
5.3	Animal carcinogenicity data .....	219
5.4	Other relevant data .....	219
5.5	Evaluation .....	220
6.	References .....	220
SUMMARY OF FINAL EVALUATIONS .....		241
CUMULATIVE INDEX TO THE <i>MONOGRAPHS</i> SERIES .....		243

## NOTE TO THE READER

The term 'carcinogenic risk' in the *IARC Monographs* series is taken to mean the probability that exposure to an agent will lead to cancer in humans.

Inclusion of an agent in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a monograph does not mean that it is not carcinogenic.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Unit of Carcinogen Identification and Evaluation, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the monographs as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Unit of Carcinogen Identification and Evaluation, so that corrections can be reported in future volumes.